Tradestie Institutional Equity Comparison Engine

INDP vs VIVS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

INDP Overall Edge

INDP Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Indaptus Therapeutics, Inc. Common Stock (INDP) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, INDP trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus VIVS at N/M Forward P/E and -10117.0% operating margin (-51.4% YoY). In options structure, INDP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
INDP N/M vs VIVS N/M Fwd P/E
Growth & Margin Winner INDP
Op Margin 0.0% vs -10117.0% ยท YoY +0.0% vs -51.4%
Momentum & Technical Winner INDP
1Y +35.5% vs -87.0% ยท 52W Pos 44% vs 5%
Options & Structure Winner INDP
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
INDP NASDAQ
Indaptus Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.13
-4.86% 1D
Market Cap $505.4M
1M Return -0.95%
1Y Return +35.5%
Forward P/E N/M
Unified AI Score
48.8 / 100 HOLD
Tech 38.0 Fund 46.0 Flow 50.0 Mom 50.0
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
1M Return +64.69%
1Y Return -86.99%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: INDP +35.5% VIVS -86.99% Spread: +122.49 pp (INDP Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
INDP TTM Op. Margin: 0.0% VIVS TTM Op. Margin: -10117.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on INDP vs VIVS. Trailing 12-month operating profitability (INDP 0.0% vs VIVS -10117.0%) and valuation multiples (INDP N/M vs VIVS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: INDP (7) vs VIVS (0)
Institutional Metric INDP VIVS Criterion Row Winner
Market Capitalization Scale $505.4M $2.4M Larger Scale INDP
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -51.4% Higher Growth INDP
Operating Margin (TTM) Profitability 0.0% -10117.0% Higher Margin INDP
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -318.0% -343.1% Higher ROE INDP
52-Week Range Position Momentum 44% ($1โ€“$6) 5% ($0โ€“$3) Stronger Trend INDP
Beta / 30D Volatility Risk Regime 0.98ฮฒ ยท 94% Vol 0.83ฮฒ ยท 480% Vol Lower Realized Risk INDP
Unified Institutional Score Composite Signal 48.8 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite INDP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full INDP vs VIVS Buy Guide
INDP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live INDP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VIVS BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live VIVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither INDP nor VIVS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.